Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress [Yahoo! Finance]
Oruka Therapeutics, Inc. (ORKA)
Company Research
Source: Yahoo! Finance
Equivalent potency to risankizumab with similar binding affinity and epitope demonstrated in several preclinical assays MENLO PARK, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today announced new preclinical data on ORKA-001, a novel extended half-life monoclonal antibody targeting IL-23p19, from its presentation at the European Academy of Dermatology and Venereology Congress (EADV). ORKA-001 has an NHP half-life of 30.3 days following SQ administration and 33.8 days following IV administration, over three times longer than risankizumab and one of the longest NHP half-lives observed for an extended half-life antibody. Projections of ORKA-001 pharmacokinetics (PK) in humans indicate that a human half-life of approximately 50 days could enable dosing once every six months, whi
Show less
Read more
Impact Snapshot
Event Time:
ORKA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ORKA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ORKA alerts
High impacting Oruka Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ORKA
News
- Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology CongressGlobeNewswire
- Oruka Therapeutics, Inc. (NASDAQ: ORKA) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.MarketBeat
- Oruka Therapeutics, Inc. (NASDAQ: ORKA) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $44.00 price target on the stock.MarketBeat
- Oruka Therapeutics, Inc. (NASDAQ: ORKA) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $41.00 price target on the stock.MarketBeat
- Oruka Therapeutics, Inc. (NASDAQ: ORKA) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.MarketBeat